| Full text | |
| Author(s): |
Patrícia Munerato
[1]
;
Maria Lúcia Azevedo
[2]
;
Maria Cecília Araripe Sucupira
[3]
;
Regina Pardini
[4]
;
Gedson Humberto Novaes Pinto
[5]
;
Márcia Catroxo
[6]
;
Inara Espinelli Souza
[7]
;
Ricardo Sobhie Diaz
[8]
Total Authors: 8
|
| Affiliation: | [1] Federal University of São Paulo. Retrovirology Laboratory
[2] Federal University of São Paulo. Retrovirology Laboratory
[3] Federal University of São Paulo. Retrovirology Laboratory
[4] Federal University of São Paulo. Retrovirology Laboratory
[5] Federal University of São Paulo. Retrovirology Laboratory
[6] Federal University of São Paulo. Retrovirology Laboratory
[7] Federal University of São Paulo. Retrovirology Laboratory
[8] Federal University of São Paulo. Retrovirology Laboratory
Total Affiliations: 8
|
| Document type: | Journal article |
| Source: | Brazilian Journal of Infectious Diseases; v. 7, n. 4, p. 236-240, 2003-08-00. |
| Abstract | |
Entry of human immunodeficiency type 1 virus (HIV-1) into target cells requires both CD4and one of the chemokine receptors. Viruses predominantly use one, or occasionally both, of the major co-receptors CCR5 and CXCR4, although other receptors, including CCR2B and CCR3, function as minor co-receptors. A 32-nucleotide deletion (delta32) within the beta-chemokine receptor 5 gene (CCR5) has been described in subjects who remain uninfected despite extensive exposition to HIV-1. The heterozygous genotype delays disease progression. This allele is common among Caucasians, but has not been found in people of African or Asian ancestry. A more common transition involving a valine to isoleucine switch in transmembrane domain I of CCR2B (64I), with unknown functional consequences, was found to delay disease progression but not to reduce infection risk. As the Brazilian population consists of a mixture of several ethnic groups, we decided to examine the genotype frequency of these polymorphisms in this country. There were 11.5% CCR5 heterozygotes among the HIV-1 infected population and 12.5% among uninfected individuals, similar to data from North America and Western Europe. The prevalence of CCR2-64I homozygotes and heterozygotes was 0.06 and 15.2%, respectively, also similar to what is known for North America and Western Europe. (AU) | |